Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YZPWM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD352A
|
|||||
| Synonyms |
SGN CD352A; SGNCD352A
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.; Ligand Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Anti-SLAMF6 mAb h20F3ec
|
Antibody Info | ||||
| Antigen Name |
SLAM family member 6 (SLAMF6)
|
Antigen Info | ||||
| Payload Name |
PBD dimer
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB).
|
|||||
| Puchem SID | ||||||
| TTD ID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.